Board Appointment
March 23 2009 - 3:01AM
UK Regulatory
TIDMAZM
RNS Number : 2622P
Alizyme PLC
23 March 2009
+----------------------------------------+-------------------------------------+
| For immediate release | 23 March 2009 |
+----------------------------------------+-------------------------------------+
ALIZYME PLC
BOARD APPOINTMENTS AND RESIGNATION
Cambridge UK, 23 March 2009: Alizyme plc (LSE:AZM) announces the appointments of
Dr Roger Lloyd and Mr Richard de Souza as Non-Executive Directors with effect
from 1 April 2009 and the resignation of Mr William Edge as a Non-Executive
Director with effect from 1 April 2009.
Dr Lloyd, aged 60, is a senior biotechnology and healthcare industry
professional with over 33 years' experience working for ICI, Zeneca and
AstraZeneca. Originally trained as a biochemist, his business development
experience has been extensive. Numerous international transactions have included
corporate acquisitions, product and technology licensing, joint ventures,
divestments, corporate merger and demerger. His international experience has
included living and working in the United States and Germany, and having
territorial responsibilities for Europe, Japan, Korea, Mexico and the Middle
East. He recently retired as Executive Director, Global Licensing in AstraZeneca
plc and is currently a non-executive director of Epistem Holdings plc. Dr Lloyd
will join the Board with effect from 1 April 2009. There are no other
disclosures relating to Dr Lloyd under Listing Rule LR 9.6.13.
Mr de Souza, aged 56, is a pharmacist who started his career at SmithKline
Beecham in manufacturing before moving through business development and
marketing roles into general management. Through his earlier career, he has been
Managing Director, then Regional Director, living in six countries worldwide and
has served as the Area Director with overall responsibility in Marketing and
Business Development for Europe, USA and international markets during his
twenty-two years with SmithKline Beecham. He served as Chairman Europe for
SmithKline Beecham and then President Europe and International for Warner
Lambert. Latterly at Shire, he was Director International, responsible for
Pharmaceuticals outside the US and Biologicals and Diagnostics globally. In 2004
he set up Archimedes Pharma Ltd, a European specialty pharmaceutical company,
where he is Chairman and CEO. Mr de Souza will join the Board with effect from 1
April 2009. There are no other disclosures relating to Mr de Souza under Listing
Rule LR 9.6.13.
Mr Edge, who has served as a Non-Executive Director since 1998, will retire
from the Board with effect from 1 April 2009.
Sir Brian Richards (Chairman) commented:
"I am delighted to welcome Roger Lloyd and Richard de Souza to the Board. I
believe they will provide invaluable advice and guidance in enabling Alizyme to
pursue its strategy and achieve its objectives of becoming a profitable,
self-sustaining biopharmaceutical product development company.
I would like to thank Bill for his many years of support and advice to Alizyme."
For further information, please contact:
+------------------------------------+---------------------------------+
| ALIZYME PLC | Tel: + 44 (0) 1223 896000 |
| Tim McCarthy, Chief Executive | |
| Officer | |
| | |
+------------------------------------+---------------------------------+
| BUCHANAN COMMUNICATIONS | Tel: + 44 (0) 20 7466 5000 |
| Lisa Baderoon | Tel: + 44 (0) 7721 413496 |
| Rebecca Skye Dietrich | |
+------------------------------------+---------------------------------+
Further information on Alizyme can be found on the Company's website:
www.alizyme.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPUUBPWUPBGBP
Alizyme (LSE:AZM)
Historical Stock Chart
From May 2024 to Jun 2024
Alizyme (LSE:AZM)
Historical Stock Chart
From Jun 2023 to Jun 2024